Patent Grant
7524857
The present invention relates to novel combinations of pyridoindolone derivatives with anticancer agents and the pharmaceutical compositions containing them.
The pyridoindolone derivatives which can be used in the present invention are the compounds of formula:
in which:
It has been found that the compounds of formula (I), which are anticancer agents, can be advantageously combined with other anticancer agents.
Preferred pyridoindolone derivatives are the compounds of formula:
in which:
Particularly preferred pyridoindolone derivatives are the compounds of formula:
in which:
More particularly preferred pyridoindolone derivatives are the compounds of formula:
in which:
By way of example, pyridoindolone derivatives according to the invention are:
NMR (200 MHz): 2.6 ppm: s: 3H; 4.1 ppm: s: 3H; 4.2 ppm: s: 3H; 7.1 ppm: d: 1H; 7.4-7.9 ppm: m: 4H; 8.3 ppm: d: 1H; 8.7 ppm: s: 1H.
NMR (200 MHz): 2.5 ppm: s: 3H; 3.8 ppm: s: 3H; 7.1 ppm: d: 1H; 7.3-7.5 ppm: m: 4H; 7;75 ppm: d: 2H; 7.8 ppm: s: 1H; 8.4 ppm: s: 1H; 11.8 ppm: s: 1H.
The compounds of formula (I) are prepared according to the process described in the document FR 97 08409.
The compounds of formula (I) were tested in vitro on a human breast cancer cell line: the line MDA-MB-231 available from the American Type Culture Collection (reference HTB26).
The assessment of the antiproliferative effect is carried out according to J. M. Derocq et al., FEBS Letters, 1998, 425, 419-425: the degree of incorporation of [3H]thymidine into the DNA of the treated cells is measured, after 96 hours of incubation of a compound of formula (I). The 50% inhibitory concentration (IC50) is defined as the concentration that inhibits the cellular proliferation by 50%.
The compounds of formula (I) have an IC50 value generally of less than 10 μM on the MDA-MB-231 line.
The compounds of formula (I) were also tested on another human breast cancer cell line, referred to as the multi-drug resistant MDR line and known as MDA-A1. This line is described by E. Collomb, C. Dussert and P. M. Martin in Cytometry, 1991, 12(1), 15-25.
The term “multi-drug resistant” which qualifies this line means that the said line is generally relatively insensitive to the chemotherapy drugs commonly used and in particular to antimitotic agents of natural origin such as paclitaxel, vincristine and vinblastine.
The compounds of formula (I) have an IC50 value that is generally less than 10 μM on the multi-drug resistant line MDA-A1.
Thus the compounds of formula (I) inhibit the proliferation of tumor cells, including that of cells showing multi-drug resistance.
Several compounds of formula (I) were also assessed in vivo on a model of xenografting of human tumors implanted subcutaneously onto SCID (Severe Combined Immuno Deficiency) immunodeficient mice.
The treatment of the animals with a compound of formula (I) started 6 to 7 days after the implantation, when the tumor reached a tumoral mass of about 60 mg. The compound was then administered orally as a solution in a solvent.
The antitumor activity was assessed when the mean tumor mass reached about 1 000 mg in the control animals, treated with solvent alone: the T/C ratio was measured, T representing the mean weight of the tumors in the treated animals and C representing the mean weight of the tumors in the control animals. A T/C ratio of less than or equal to 42% is considered as indicating a significant antitumor activity according to Stuart T et al., in J. Med. Chem., 2001, 44 (11), 1758-1776. For an administered daily dose of between 50 and 300 mg/kg, certain compounds of formula (I) gave a T/C ratio of less than 20%.
The antiproliferative effects of the combination of a compound of formula (I) with another anticancer agent were measured on the MDA-A1 line, the “multi-drug resistant” line referred to above, according to the referenced technique (J. M. Derocq et al.). The IC50 value obtained for the anticancer agent alone was compared with that obtained for the combination of the same anticancer agent with a compound of formula (I). A marked decrease in the IC50 value was observed. The IC50 values can be divided by a factor ranging from 2 to 100 and even above 100 for certain pyridoindolone derivatives of formula (I) combined with another anticancer agent.
By way of example, the IC50 value obtained for paclitaxel alone was compared with that obtained for the combination of paclitaxel with 1,6,9-trimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one. The IC50 value is divided by a factor ranging from 14 to 100 depending on the concentrations of 1,6,9-trimethyl-3-phenyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one used.
The results of the tests show a synergistic effect and potentiation of the antiproliferative effects of the components of the combinations of the invention.
According to the present invention, the compound(s) of formula (I) are administered in combination with one (or more) anticancer active principle(s). These active principles can be, in particular, antitumor compounds such as alkylating agents, alkyl sulfonates (busulfan), dacarbazine, procarbazine, nitrogen mustards (chlormethine, melphalan or chlorambucil), cyclophosphamide or ifosfamide; nitrosoureas such as carmustine, lomustine, semustine or streptozocin; antineoplastic alkaloids such as vincristine or vinblastine; taxanes such as paclitaxel; antineoplastic antibiotics such as actinomycin; intercalating agents; antineoplastic antimetabolites, folate antagonists, methotrexate; purine synthesis inhibitors; purine analogs such as mercaptopurine or 6-thioguanine; pyrimidine synthesis inhibitors, aromatase inhibitors, capecitabine, and pyrimidine analogs such as fluorouracil, gemcitabine, cytarabine and cytosine arabinoside; brequinar; anticancer hormonal agonists and antagonists including tamoxifen; kinase inhibitors, imatinib; growth factor inhibitors; some antiinflammatory agents which can be used in the treatment of cancer such as pentosane polysulfate, corticosteroids, prednisone or dexamethasone; anti-topoisomerases such as etoposide, antracyclines including doxorubicin, bleomycin, mitomycin and methramycin; anticancer metallic complexes, platinum complexes, cisplatin, carboplatin or oxaliplatin; alpha-interferon, triphenylthio-phosphoramide or altretamine; anti-angiogenic agents; immunotherapy adjuvants.
The combinations of the invention are useful for the prevention and treatment of diseases caused or exacerbated by the proliferation of tumor cells, such as primary or metastatic tumors, carcinomas and cancers, in particular: breast cancer; lung cancer; cancer of the small intestine, cancer of the colon and of the rectum; cancer of the respiratory pathways, of the oropharynx and of the hypopharynx; cancer of the esophagus; liver cancer, stomach cancer, cancer of the bile ducts; cancer of the bile vesicle, cancer of the pancreas; cancers of the urinary pathways including the kidneys and the urothelium, cancer of the bladder; cancers of the female genital tract including cancer of the uterus, of the cervix and of the ovaries, chloriocarcinoma and trophoblastoma; cancers of the male genital tract including cancer of the prostate, of the seminal vesicles and of the testicles, and tumors of the germinal cells; cancers of the endocrine glands including cancer of the thyroid, of the pituitary and of the adrenal glands; skin cancers, including hemangiomas, melanomas and sarcomas, including Kaposi's sarcoma; tumors of the brain, of the nerves, of the eyes, of the meninges, including astrocytomas, gliomas, glioblastomas, retinoblastomas, neurinomas, neuroblastomas, schwannomas and meningiomas; tumors arising from hematopoietic malignant tumors including leukemias, chloromas, plasmacytomas, fungoid mycosis, lymphoma or T cell leukemia, non-Hodgkin lymphoma, malignant hemopathies and myelomas.
A subject of the present invention is also pharmaceutical compositions containing, as active principle(s), a therapeutically effective amount of at least one compound of formula (I), or a pharmaceutically acceptable salt, a hydrate or a solvate of the said compound, and a therapeutically effective amount of one (or more) other anticancer active principle(s), and also one or more pharmaceutically acceptable excipients.
The said excipients are chosen, according to the pharmaceutical form and the desired mode of administration, from the usual excipients that are known in the prior art.
The pharmaceutical compositions of the present invention may be prepared for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, or for administration via any other suitable route, to man and animals for the prevention or treatment of the above diseases.
The compounds of formula (I) above may be used at daily doses of from 0.002 to 2 000 mg per kilogram of bodyweight of the mammal to be treated, preferably at daily doses of from 0.1 to 300 mg/kg. In man, the dose may preferably range from 0.02 to 10 000 mg per day and more particularly from 1 to 3 000 mg depending on the age of the individual to be treated or the type of treatment (prophylactic or curative).
The anticancer active principles with which the compounds of formula (I) are combined are used at the usual doses.
The suitable administration forms comprise oral forms such as tablets, soft or hard gel capsules, powders, granules and oral solutions or suspensions, sublingual, buccal, intratracheal, intraocular, intranasal or inhaled administration forms, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. For topical application, the combinations of the invention may be used in creams, gels, ointments or lotions.
According to the usual practice, the dosage that is suitable for each patient is determined by the doctor according to the mode of administration, the age, the weight and the response of the said patient.
According to another aspect of the invention, the compound(s) of formula (I) and one (or more) other anticancer active principle(s) may be administered simultaneously, sequentially or separately over time, for the treatment of diseases caused or exacerbated by the proliferation of tumor cells.
The combinations of the invention may be in the form of a kit containing, firstly, at least one compound of formula (I) and, secondly, one (or more) other anticancer active principle(s).
According to another of its aspects, the invention also relates to a method for treating diseases caused or exacerbated by proliferation of tumor cells, which consists in administering to an individual in need thereof a therapeutically effective amount of at least one compound of formula (I) in combination with one (or more) other anticancer active principle(s).
| Number | Date | Country | Kind |
|---|---|---|---|
| 01 05843 | Apr 2001 | FR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/FR02/01450 | 4/26/2002 | WO | 00 | 10/27/2003 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO02/087575 | 11/7/2002 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4263304 | Ishizumi et al. | Apr 1981 | A |
| 4835160 | Bisagni et al. | May 1989 | A |
| 5035252 | Mondre | Jul 1991 | A |
| 5880126 | Skuballa et al. | Mar 1999 | A |
| 6486177 | Zeldis et al. | Nov 2002 | B2 |
| 6503888 | Kaplitt et al. | Jan 2003 | B1 |
| 6967203 | Bourrie et al. | Nov 2005 | B2 |
| 20020156016 | Minuk | Oct 2002 | A1 |
| 20070129365 | Bourrie | Jun 2007 | A1 |
| Number | Date | Country |
|---|---|---|
| 2003999 | Nov 1969 | FR |
| 2 765 581 | Jan 1999 | FR |
| 2765582 | Jan 1999 | FR |
| 9708409 | Jan 1999 | FR |
| WO 0109129 | Feb 2001 | IT |
| 833971 | May 1981 | SU |
| 833972 | May 1981 | SU |
| WO9951597 | Oct 1999 | WO |
| WO0109129 | Feb 2001 | WO |
| WO2004037821 | May 2004 | WO |
| WO2004041817 | May 2004 | WO |
| WO2005108398 | Nov 2005 | WO |
| WO2007045758 | Apr 2007 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20040122036 A1 | Jun 2004 | US |
